Targeted Radioligand Therapy and Immunotherapy for Cancer Treatment
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 20 February 2025 | Viewed by 2086
Special Issue Editors
Interests: oncology; radioactivity; cancer treatment
Interests: radiopharmaceutical therapy; radiochemistry; tumor microenvironment; tumor immunology; precision oncology; molecular targeting; molecular imaging; radiopharmaceuticals; targeted therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are delighted to announce a call for submissions for this Special Issue of the International Journal of Molecular Sciences. This Special Issue aims to explore the latest developments, challenges and innovations at the intersection of targeted radioligand therapy and immunotherapy as potent modalities for cancer treatment.
Targeted radioligand therapy and immunotherapy have emerged as transformative approaches within the oncological landscape, offering new avenues for personalized and effective cancer treatment. The combination of these modalities holds significant promise in enhancing treatment outcomes, overcoming resistance mechanisms and improving patient survival rates.
We welcome original research articles, reviews, clinical studies, case reports and perspectives addressing various aspects of targeted radioligand therapy and immunotherapy in cancer treatment, including but not limited to, the following:
- Mechanisms of action and biological interactions between targeted radioligand therapy and immunotherapy;
- Preclinical and clinical efficacy of combined targeted radioligand therapy and immunotherapy in different cancer types;
- Radiobiology and immunobiology of the tumor microenvironment in the context of combined therapy;
- Novel strategies for optimizing the combination of targeted radioligand therapy and immunotherapy;
- Novel biomarkers and prediction of response to combined therapy;
- Technological advancements and innovations in targeted radioligand therapy and immunotherapy delivery;
- Immunotherapy-based approaches for overcoming resistance to targeted radioligand therapy;
- Radiomics and immunogenomics in predicting treatment response and patient outcomes;
- Challenges and future directions in the clinical integration of targeted radioligand therapy and immunotherapy.
Dr. Jinda Fan
Dr. Carolina de Aguiar Ferreira
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted radioligand therapy
- immunotherapy
- receptor targeting
- tumor-specific antigens
- immune checkpoint inhibitors
- radiosensitization
- tumor microenvironment
- combination therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
